Alcon Inc. (ALC): what the price assumes

In the published model solve dated 2026-Q2, anchored at $72.01, Alcon Inc. (ALC) is priced for +20.0% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-31 · Source: https://boothcheck.com/report/ALC

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.3% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: n/a

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=17)

Solvency

Bullet Takeaways

• Alcon's reported profits look nothing like the business the price is paying for: first-quarter 2026 diluted earnings were 39 cents a share against the company's own core measure of 85 cents, on an operating margin of 10.9%.
• Tariffs are the live external risk, and the FY2025 20-F puts a number on them: Additional tariffs incurred in the United States and China during the twelve months ended December 31, 2025 amounted to $91 million, roughly a tenth of a year's reported operating profit.
• The next test is whether the raised 2026 outlook holds, with constant-currency sales guided to grow 5% to 7% and the board authorizing up to 1.5 billion dollars of buybacks over three years.

Bull Case

Here is the number that does not fit. In the first quarter of 2026 Alcon earned 39 cents a share on a reported basis and 85 cents on the core measure it uses to describe the underlying business, with a reported operating margin of 10.9% on sales of 2.7 billion dollars. Two figures, one quarter, and the difference between them is the accounting for intangible assets and other items the company excludes. Anyone valuing this company off the reported line is measuring a spin-off's balance sheet as much as an eye-care business.

That distinction matters because of what the products actually are. Alcon sells the lens implanted during cataract surgery and the equipment used to implant it, plus contact lenses and dry-eye treatments, and its FY2025 annual report describes the surgical range as Across our Surgical portfolio, we sell a tiered offering of products intended to meet the specific needs of customers in markets around the world at different price points. A tiered range means the premium end can grow faster than the market without needing more procedures, which is precisely the mechanism management pointed at in the first quarter: new launches including the Unity surgical systems, PanOptix Pro, Tryptyr and Precision7.

The scale behind those launches is not easily replicated. The company states in its annual filing that We believe we have made one of the largest commitments to research and development of any surgical and vision care company, and pairs it with the manufacturing side of the same argument: Furthermore, our global manufacturing and supply chain allows us to leverage economies of scale and reduce cost per unit as we ramp up production. In a field where a surgeon's choice of lens platform tends to follow the equipment already installed in the operating room, being the default supplier of both is worth more than a percentage point of price.

Capital allocation turned decisively toward shareholders this year. STAAR Surgical's holders rejected Alcon's raised 30.75-dollar-a-share offer at the vote on January 6, 2026, ending a deal first announced in August 2025 with no termination fee owed. Four months later the board authorized the repurchase of up to 1.5 billion dollars of shares over roughly three years, with the shares to be cancelled. The share count has been essentially flat for four years, so cancellation is a real reduction rather than an offset to issuance.

Which leaves the question of whether the balance sheet can carry it, and it can. Net borrowings sit near 2.6 billion dollars, about 2.55 times operating profit, with operating income covering the interest bill roughly 5.8 times over. That is a company with room to buy its own shares and keep funding the launch pipeline at the same time, without the kind of leverage that turns a soft quarter into a financing problem.

The bull case reduces to one proposition: the reported margin is a floor rather than a description. Alcon converts about 10.6% of revenue into operating profit today while the wider device cohort runs from 14.0% at ZBH to 19.7% at SYK and 34.2% at RMD. Close even part of that gap and reported operating profit compounds quickly from a low base, which is exactly the shape the price is paying for.

Bear Case

The external variable with the most leverage here is not demand, it is trade policy, and Alcon has already put a figure on it. Its FY2025 annual report discloses that Additional tariffs incurred in the United States and China during the twelve months ended December 31, 2025 amounted to $91 million, of which $67 million was recognized in "Cost of net sales" in the Consolidated Income Statement. Against a business earning roughly a billion dollars of reported operating profit, that is close to a tenth of the total, arriving from a policy decision nobody in the company influences. The same filing declines to call the situation stable: Temporary tariff agreements and suspensions have proven volatile and subject to modification or reversal without advance notice. A manufacturer shipping surgical equipment between the United States, Europe and China is exposed at every border it crosses.

Currency runs the same way and is currently flattering the picture. First-quarter 2026 sales rose 10% as reported but 6% in constant currency. Four of those ten points came from the exchange rate, and a Swiss-domiciled company reporting in dollars has no more control over that than over the tariff schedule. Guidance for the full year is 5% to 7% constant-currency sales growth, which is the honest underlying pace.

Now put that against what the price requires. At $67.88 the market pays roughly 35 times company-wide operating profit, and the arithmetic that supports it needs today's economics to hold for about five and a half years with profit compounding at the ceiling of what the business can fund from its own cash. Of companies that have grown that fast, only about 28% kept it up for that long. With underlying sales growing in the mid-single digits, essentially all of the required improvement has to come from margin, and margin is precisely where tariffs, currency and price concessions land first.

The competitive setting does not make that easier. The annual report is blunt about it: The eye care industry is highly competitive and subject to rapid technological change and evolving industry requirements and standards. In the cohort of listed device makers, Alcon's roughly 5% trailing revenue growth is the slowest on the list, behind MMSI at 11.1%, RMD at 10.3%, ZBH at 9.2% and SYK at 8.8%. Its reported operating margin of about 10.6% is second-lowest, ahead only of BLCO at 4.4%. The premium multiple is being paid on the weakest reported numbers in the group, which is only justified if the reported numbers are wrong in the specific direction the bull expects.

The valuation methods agree on the shape of the risk. Only the forward-growth approaches reach today's price. The asset-value, earnings-power and peer-multiple methods all land far below it, which tells you the price is not supported by what the company currently earns or owns but by what it is expected to earn later. Solvency is not the issue: leverage near 2.55 times operating profit with interest covered about 5.8 times is comfortable. The issue is duration. This is a bet that another five and a half years of uninterrupted improvement arrive on schedule, in an industry where the improvement can be taxed away at a border.

Valuation

Thirty-five times operating profit is the headline, and the first job is deciding whether that operating profit means anything. Reported operating margin ran about 10.6% over the trailing period and 10.9% in the first quarter of 2026, while the same quarter produced core earnings of 85 cents a share against 39 cents reported. The reported line carries the amortization of assets the company acquired, most of them inherited when it was separated into a standalone business. Investors paying 35 times that figure are implicitly paying a much lower multiple of what the company says it actually earns, and the entire valuation argument sits in the space between those two numbers.

What the price requires is a long run rather than a fast one. The assumption that fits today's level is roughly five and a half years of today's economics with operating profit compounding at the fastest pace the business can finance internally. Historically only about 28% of companies growing at that rate sustained it that long, which is what makes the requirement demanding: not the rate itself, which Alcon has touched, but the number of consecutive years it has to persist. Each percentage point of change in the assumed cost of capital moves that required horizon by roughly two years, so treat it as a range rather than a measurement.

The methods split cleanly. Only the forward-growth approaches reach the price. The peer-multiple and earnings-power methods land far below it, and the asset-value methods land furthest below of all, for a reason worth understanding rather than reciting: the book value they work from is dominated by intangible assets recognised at separation, and the accounting return on that inflated book is low by construction. That does not make the asset methods wrong, it makes them the wrong lens for a company whose value sits in installed surgical platforms and product registrations rather than in recorded net assets. When only the growth family reaches the price, the premium is a bet on durability, and the static methods have no way to frame it.

Among listed peers the position is unusual. Alcon's trailing operating margin near 10.6% sits below COO at 11.8%, MMSI at 12.2%, ZBH at 14.0%, MDT at 17.8%, STE at 18.6%, SYK at 19.7% and RMD at 34.2%, and its trailing revenue growth of about 5% is the slowest in that group. Reported numbers alone would not earn this multiple anywhere in the cohort.

The balance sheet is the least controversial part of the picture. Net borrowings near 2.6 billion dollars, about 2.55 times operating profit, interest covered roughly 5.8 times, and a share count that has barely moved in four years, now paired with an authorization to repurchase up to 1.5 billion dollars of stock over three years. None of that is what the price hinges on. The price hinges on how many consecutive years the improvement in reported profitability continues, and the tariff line in the annual report is a reminder that the answer is not entirely the company's to give.

Catalysts

The most consequential recent event for Alcon was one that did not happen. STAAR Surgical's stockholders voted down the company's raised 30.75-dollar-a-share offer on January 6, 2026, ending a transaction first announced in August 2025 at 28 dollars a share, with no termination fee payable by either side. That closed off an expansion into implantable lenses for younger patients and freed the capital behind it.

Where that capital went became clear with first-quarter results on May 5, 2026. The board authorized the repurchase of up to 1.5 billion dollars of shares, to be executed over roughly three years on a second trading line and then cancelled, and management raised full-year guidance for core earnings growth to 10% to 13% in constant currency from 9% to 12%, holding constant-currency sales growth at 5% to 7%. Sales in the quarter were 2.7 billion dollars, up 10% as reported and 6% in constant currency, with free cash flow of 279 million dollars.

The launch cycle is what the guidance rests on. Management attributed the quarter's growth to the Unity surgical systems, PanOptix Pro, Tryptyr and Precision7, and the coming quarters are where those products either take share in the operating room or settle into a slower ramp. Watch the constant-currency line rather than the reported one, since currency added four points of growth in the first quarter and can subtract them just as easily.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• COO (The Cooper Companies, Inc.)
• FY2025 10-K: …blood and cord tissue storage (and other cryostorage) businesses, we interact directly with our customers and collect and maintain personal information regarding our customers and donors. Acquisitions like this could subject us to additional regulatory and consumer liability risk and the cost of analyzing and…
• FY2025 10-K: …of competitive products or services, such as new silicone hydrogel products or contraceptive technologies, into the market by our competitors; and the emergence of newer and more competitive products or services. We operate in the highly competitive health care industry, and we cannot be assured that we will be able…
• BLCO (Bausch & Lomb Corp)
• FY2025 10-K: …update these initiatives as well as to create new opportunities to provide our customers with the necessary resources to use our products safely and effectively. Customers that accounted for 10% or more of our total revenues for 2025 and 2024 were as follows: 2025 2024 McKesson Corporation 10 % 10 % Cardinal Health,…
• FY2025 10-K: …sales opportunities, which could adversely impact the traditional eye care professional ("ECP") channel in which we have a significant presence. The market for contact lenses is intensely competitive and is characterized by declining sales volumes for older and reusable product lines and growing demand for daily…
• STE (STERIS plc)
• FY2025 10-K: …to outsourced instrument reprocessing services. In addition, our procedural products also include endoscopy accessories, instruments, and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas. Our AST segment supports medical…
• FY2025 10-K: …changes for comparability, as required. For more information, refer to Note 4 titled, "Discontinued Operations." Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. Our Healthcare segment provides a comprehensive…
• MDT (Medtronic plc)
• FY2025 10-K: …operating profit in the budget and forecasting process and to monitor budget and forecast variances versus actual when assessing segment performance and allocating capital resources to each segment. The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be…
• FY2025 10-K: …services from which the Neuroscience Portfolio segment derives its revenues include those focused on neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as various areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. The…
• SYK (STRYKER CORP)
• FY2025 10-K: …products restricts competitors from duplicating these unique designs and features. We seek to obtain patent protection on our products whenever appropriate for protecting our competitive advantage. On December 31, 2025 we owned approximately 5,600 United States patents and approximately 9,000 patents in other…
• FY2025 10-K: …sales by 0.5% . Excluding the 0.7% impact of acquisitions and divestitures, net sales in constant currency increased by 8.7% from increased unit volume. The unit volume increase was due to higher shipments across all Orthopaedics businesses. Gross Pro fit Gross profit was $ 16,065 , $ 14,440 and $ 13,058 in 2025 ,…
• ZBH (ZIMMER BIOMET HOLDINGS, INC.)
• FY2025 10-K: …for our knees, hips, and S.E.T. products, our major competitors include Johnson & Johnson MedTech (formerly the DePuy Synthes Companies of Johnson & Johnson), Stryker Corporation and Smith & Nephew plc. There are smaller competitors in these product categories as well that focus on smaller subsegments of the…
• FY2025 10-K: ") is our President and Chief Executive Officer . Our CODM allocates resources to achieve our operating profit goals through three operating segments. These operating segments, which also constitute our reportable segments, are Americas; EMEA; and Asia Pacific. Our CODM evaluates performance based upon segment…
• MMSI (MERIT MEDICAL SYSTEMS INC)
• FY2025 10-K: …of cardiology, radiology, oncology, critical care and endoscopy. This marketplace is characterized by rapid technological advancement, industry and customer consolidation, customer demands for price reductions, regulatory reform, and evolving patient needs. We compete with companies of varying sizes. Many of our…
• FY2025 10-K: …("Teleflex"), Cook Medical Incorporated ("Cook Medical"), Medtronic plc ("Medtronic"), Boston Scientific Corporation ("Boston Scientific"), and Becton, Dickinson and Company ("BD"). Our primary competitors in our cardiac intervention market are BD, Teleflex, Medtronic, Abbott Laboratories, Terumo Corporation, Edwards…
• RMD (ResMed Inc.)
• FY2025 10-K: …Care Software business for the year ended June 30, 2025 was $641.4 million, compared to $584.1 million for the year ended June 30, 2024, an increase of $57.3 million or 10%. The increase was driven by continued growth in the Home Medical Equipment, or HME, and MEDIFOX DAN verticals within our Residential Care…
• FY2025 10-K: …rates and financial markets. Our combined sales of medical devices into Iran, Russia and Ukraine did not constitute a material portion of our total revenue in fiscal year 2025. Further escalation of geopolitical tensions, or new geopolitical tensions, could have a broader impact that expands into other markets where…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.